Raabe A, Seifert V
Department of Neurosurgery, University of Leipzig, Germany.
Neurosurg Rev. 2000 Sep;23(3):136-8. doi: 10.1007/pl00011944.
The objective of our study was to investigate S-100B protein as a serum marker of brain cell damage after severe head injury. Eighty-three patients with severe head injury (Glasgow Coma Scale < or =8) were included in this prospective study. Venous blood samples for S-100B protein were taken after admission and every 24 h for a maximum of 10 consecutive days. Outcome was assessed at 6 months using the Glasgow Outcome Scale. In this study, we analysed the preliminary results from the outcomes of 25 patients at 6 months. Levels of S-100B were significantly higher in patients with unfavourable outcome compared to those with favourable outcome. In patients with favourable outcome, slightly increased initial levels of S-100B returned to normal within 3 to 4 days. In patients with unfavourable outcome, initial levels were markedly increased, with a tendency to decrease from day 1 to day 6. After day 6, there was a secondary increase in serum S-100B, indicating secondary brain cell damage. Our preliminary results suggest that serum S-100B protein might be a promising biochemical marker which may provide additional information on the extent of primary injury to the brain and the prediction of outcome after severe head injury.
我们研究的目的是调查S-100B蛋白作为重度颅脑损伤后脑细胞损伤的血清标志物。本前瞻性研究纳入了83例重度颅脑损伤患者(格拉斯哥昏迷量表评分≤8分)。入院后采集用于检测S-100B蛋白的静脉血样本,此后每24小时采集一次,最多连续采集10天。在6个月时使用格拉斯哥预后量表评估预后。在本研究中,我们分析了25例患者6个月时预后的初步结果。预后不良的患者S-100B水平显著高于预后良好的患者。在预后良好的患者中,S-100B初始水平略有升高,在3至4天内恢复正常。在预后不良的患者中,初始水平显著升高,从第1天到第6天有下降趋势。第6天后,血清S-100B出现二次升高,提示继发性脑细胞损伤。我们的初步结果表明,血清S-100B蛋白可能是一种有前景的生化标志物,可为重度颅脑损伤后脑原发性损伤的程度及预后预测提供额外信息。